December 2024

— Treatment with both combination regimens demonstrates synergistic anti-tumor activity, supporting planned combination strategy for EO-3021 in patients with gastric or gastroesophageal junction (GEJ) cancer – — On-track to initiate dosing in combination portion of the ongoing Phase 1

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: